Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Bbio save search
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.47%
H: 2.05%
C: -0.59%
nulibry authorization treatment for therapeutics
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Published: 2024-02-05 (Crawled : 12:30) - bridgebio.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -1.21%
H: 1.43%
C: 0.39%
pharma drug food treatment application
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Published: 2023-12-05 (Crawled : 12:30) - bridgebio.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -0.75%
H: 1.58%
C: -0.32%
pharma drug food treatment application submission
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
Published: 2023-11-27 (Crawled : 13:30) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.64%
H: 0.02%
C: -0.66%
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -0.2%
H: 2.17%
C: 0.91%
ceo change treatment
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
Published: 2023-10-03 (Crawled : 12:00) - bridgebio.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.0%
H: 1.4%
C: 0.08%
bbp-631 partnership multi-year bbp-812 therapy
BridgeBio Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 65.5%
H: 7.78%
C: -8.17%
velocity positive results achondroplasia phase 2
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Published: 2022-09-20 (Crawled : 13:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -0.09%
H: 4.17%
C: 2.13%
nulibry treatment pharma therapeutics authorization
BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)
Published: 2022-08-18 (Crawled : 12:20) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: -0.85%
H: 2.28%
C: 1.81%
bbp-671 treatment pharma trial potential
BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Published: 2022-08-10 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 3.97%
H: 5.9%
C: 3.99%
nulibry treatment pharma israel approval therapeutics
BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
Published: 2022-07-25 (Crawled : 12:00) - prnewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.59%
H: 8.42%
C: 8.03%
nulibry treatment pharma chmp therapeutics positive
National Organization for Rare Disorders (NORD) honors NULIBRY® (fosdenopterin) for the Treatment of molybdenum cofactor deficiency (MoCD) Type A with 2022 Industry Innovation Award
Published: 2022-06-27 (Crawled : 15:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.22%
H: 2.22%
C: 1.3%
nulibry treatment rare innovation
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Published: 2022-05-20 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 3.42%
H: 2.83%
C: 2.7%
ptr-01 treatment pharma trial positive therapy
LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China
Published: 2021-12-21 (Crawled : 13:30) - biospace.com/
LIAN | $4.92 0.41% 0.41% 410K
|
Professional, Scientific, and T...
|
| O: 6.24%
H: 0.13%
C: -6.63%
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.07%
H: 4.03%
C: 2.15%
treatment china
BridgeBio Pharma Announces First Publication of Preclinical Data for its Potentially Best-in-Class SHP2 Inhibitor Designed for Treatment of Resistant Cancer, Showing Response in Established Non-small Cell Lung Cancer Models
Published: 2021-10-07 (Crawled : 22:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.2%
H: 3.57%
C: -0.56%
treatment lung cancer potential cancer preclinical pre-clinical designation
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Therapy for the Treatment of Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Published: 2021-09-15 (Crawled : 12:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.47%
H: 1.06%
C: -1.02%
treatment fda fda fast track fast track therapy fast track designation designation
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1
Published: 2021-06-01 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.88%
H: 1.61%
C: 1.09%
treatment fda fda fast track fast track fast track designation designation pharma
BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research
Published: 2021-04-13 (Crawled : 12:00) - globenewswire.com
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.43%
H: 2.42%
C: 0.76%
disease treatment genetic potential collaboration research
BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.43%
H: 2.42%
C: 0.76%
treatment genetic cancer collaboration pharma
BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions
Published: 2021-04-13 (Crawled : 12:00) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 0.43%
H: 2.42%
C: 0.76%
treatment genetic collaboration announces collaboration pharma
BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
Published: 2020-12-01 (Crawled : 22:02) - biospace.com/
BBIO | $24.74 -0.84% -0.85% 2M
|
Health Technology
|
| O: 1.49%
H: 2.78%
C: 0.27%
fda drug fda acceptance treatment new drug application pharma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
WLGS | $0.59 18.0% 17.9% 2.3M
|
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
MGOL 4 | $0.229 -4.18% 13.72% 420K
|
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
BQ | $0.269 1.51% 11.15% 1.1M
|
Consumer Non-Durables
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.